Title:Network Pharmacology-Based and Molecular Docking Analysis of Resveratrol’s
Pharmacological Effects on Type I Endometrial Cancer
Volume: 22
Issue: 10
Author(s): Zixing Zhong, Xin Guo and Yanmei Zheng*
Affiliation:
- Department of Obstetrics, People’s Hospital of Hangzhou Medical College, Zhejiang Provincial People’s Hospital, Hangzhou
310014, China
Keywords:
Endometrial cancer, gynecological cancer, cancer agent, hydrophobic interaction, antagonist, molecular docking.
Abstract:
Background: Resveratrol is a natural polyphenol commonly seen in foods. It has demonstrated an inhibitive
effect on endometrial cancer, but the molecular action is still not known.
Objective: We aimed to use network pharmacology to systematically study the possible mechanisms of resveratrol’s
pharmacological effects on type I endometrial cancer.
Methods: Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) were used
to predict resveratrol’s possible target genes. They were then converted to UniProt gene symbols. Simultaneously, type
I endometrial cancer-related target genes were collected from GeneCards. All data were pooled to identify common
target genes. The protein-protein interaction (PPI) network was constructed and further analyzed via STRING Online
Database. Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
were also performed afterward. To visualise resveratrol's overall pharmacological effects on type I endometrial
cancer, a network of drug components-target gene-disease (CTD) was constructed. Then, we performed in silico molecular
docking study to validate the possible binding conformation between resveratrol and candidate targets.
Results: There are 150 target genes of resveratrol retrieved after UniProt conversion; 122 of them shared interaction
with type I endometrial cancer. Some important oncogenes and signaling pathways are involved in the process of
resveratrol’s pharmacological effects on endometrioid cancer. Molecular docking analysis confirmed that hydrogen
bonding and hydrophobic interaction are the main interaction between resveratrol and its targets.
Conclusion: We have explored the possible underlying mechanism of resveratrol in antagonising type I endometrial
cancer through a network pharmacology-based approach and in-silico verification. However, further experiments are
necessary to add to the evidence identifying resveratrol as a promising anti-type I endometrial cancer agent.